ArticleDiscover oncology2025
Discovery of drug candidate to inhibit bronchogenic carcinoma genes biomarkers based on drug repurposing.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLung cancer is one of the most common and challenging cancers to treat. Advances in research have led to the development of targeted drug therapies that provide suitable options for patients with bronchogenic lung cancer. The aim of the current study is to inhibit genes that have been introduced as biomarkers for the diagnosis of bronchogenic lung cancer.
methodsThis study leverages computational methods to identify repurposable drugs targeting key biomarkers—MLKL, YWHAG, OAS3, TFRC, NXA2, CDK6, NTN1, CD59, RRAS2, and CYP51A1—for cancer treatment. As a primary screening tool, AutoDock Vina was employed for molecular docking to evaluate the binding affinity of existing drugs against these targets. Following the initial screening, molecular dynamics simulations were utilized to select the most stable and ideal drug candidates with specific inhibitory therapeutic properties from the pool identified by docking. This integrated workflow demonstrates an efficient path for discovering new therapeutic uses for existing drugs against a defined panel of cancer biomarkers.
resultsFor the ten genes under investigation, structurally reliable PDB entries were chosen as the basis for subsequent analyses. The herbal compound Dracorubin, along with 2,299 ligands collected from the PubChem database, was assessed. Molecular dynamics simulations indicated that Dracorubin sustained stable and meaningful inhibitory interactions with the proposed biomarkers.
conclusionThe study aimed to find new uses for existing drugs for Bronchogenic lung cancer. Using computational methods like molecular docking and dynamics, researchers prioritized compounds that bind strongly to target proteins. These candidate drugs, prioritize a computational lead requiring experimental validation of Bronchogenic lung cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.